Research programme: ADAR1 targeting therapeutics - BridGene Biosciences
Latest Information Update: 30 Oct 2024
At a glance
- Originator BridGene Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action ADAR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer